ArticleTranslational cancer research2021
Pathological prognostic factors for post-resection survival in patients with hepatocellular carcinoma associated with non-alcoholic fatty liver disease.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Pooled it
- An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians.Biomedicines · 2023Review
- Is Ki-67 a prognostic factor for post-operation survival in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma?Translational cancer research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD) is steadily increasing. However, little is known about the characteristics of these patients or the factors affecting their prognosis. Our aim was to evaluate the pathological prognostic factors associated with survival in NAFLD patients.
methodsThis was a retrospective cohort study of 575 patients who underwent resection of HCC between January 2004 and December 2018. HCC was associated purely with NAFLD or hepatitis B virus (HBV) based on the pathology and viral markers. The pathological markers of HCC were compared between patients with pure NAFLD and patients with pure HBV.
resultsThe pathological factors were similar between the two groups. There were no differences in overall survival (OS; P=0.283) or recurrence-free survival (RFS; P=0.990) between the pure NAFLD and pure HBV groups. The NAFLD group had a similar local RFS (P=0.785) but a better systemic RFS compared with the HBV group, (P=0.089). In multivariable analysis using bootstrapping with resampling and replacement of data, no single factor was significantly associated with RFS. However, the Ki-67 labeling index [P=0.022; bootstrap 95% confidence interval (CI): 0.000-0.919] was the only independent factor associated with systemic recurrence in the NAFLD group.
conclusionsIn patients with HCC associated with NAFLD, the Ki-67 labeling index determined by immunohistochemistry may predict the risk of systemic recurrence following resection, allowing for stricter monitoring protocols for such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.